FMP
Virtus LifeSci Biotech Clinical Trials ETF
BBC
AMEX
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.
24.4 USD
0.4064 (1.67%)
About
ceo
N/A
sector
Financial Services
industry
Asset Management
website
N/A
exchange
AMEX
Description
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.
CIK
0001559109
ISIN
US26923G3011
CUSIP
26923G301
Address
N/A
Phone
NA
Country
US
Employee
N/A
IPO Date
Dec 17, 2014
Key Executives
